Patents by Inventor Robert P. Lanza

Robert P. Lanza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220347228
    Abstract: Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.
    Type: Application
    Filed: April 13, 2022
    Publication date: November 3, 2022
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Robert P. Lanza, Wei Wang, Shi-Jiang Lu
  • Publication number: 20220257663
    Abstract: Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.
    Type: Application
    Filed: December 21, 2021
    Publication date: August 18, 2022
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Robert P. Lanza, Shi-Jiang Lu, Wei Wang
  • Patent number: 11400118
    Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: August 2, 2022
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
  • Patent number: 11369638
    Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: June 28, 2022
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
  • Publication number: 20220160778
    Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.
    Type: Application
    Filed: November 2, 2021
    Publication date: May 26, 2022
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Erin Anne Kimbrel, Robert P. Lanza, Jianlin Chu, Nicholas Arthur Kouris
  • Patent number: 11241460
    Abstract: Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: February 8, 2022
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Robert P. Lanza, Shi-Jiang Lu, Wei Wang
  • Publication number: 20210308187
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Application
    Filed: November 12, 2020
    Publication date: October 7, 2021
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Irina V. Klimanskaya, Robert P. Lanza
  • Publication number: 20210182552
    Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.
    Type: Application
    Filed: September 16, 2020
    Publication date: June 17, 2021
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Erin Anne Kimbrel, Robert P. Lanza, Jianlin Chu, Nicholas Arthur Kouris
  • Publication number: 20210161964
    Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.
    Type: Application
    Filed: December 8, 2020
    Publication date: June 3, 2021
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
  • Patent number: 10894065
    Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: January 19, 2021
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
  • Publication number: 20200405767
    Abstract: This disclosure provides the first description of hESC-derived cells transplanted into human patients. Results are reported for one patient with each of Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD). Controlled hESC differentiation resulted in near-100% pure RPE populations. Immediately after surgery, hyperpigmentation was visible at the transplant site in both patients, with subsequent evidence the cells had attached and integrated into the native RPE layer. No signs of inflammation or hyperproliferation were observed. The hESC-derived RPE cells have shown no signs of rejection or tumorigenicity at the time of this report. Visual measurements suggest improvement in both patients.
    Type: Application
    Filed: July 13, 2020
    Publication date: December 31, 2020
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Roger Gay, Irina V. Klimanskaya, Robert P. Lanza
  • Patent number: 10584313
    Abstract: The present invention relates generally to the field of somatic cell nuclear transfer (SCNT) and to the creation of cloned animals and cells. The disclosure relates to a method of cloning a mammal, obtaining pluripotent cells such as embryonic stem cells, or for reprogramming a mammalian cell using an oocyte and a fertilized embryo.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: March 10, 2020
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Robert P. Lanza, Young Gie Chung
  • Publication number: 20200023011
    Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.
    Type: Application
    Filed: August 1, 2019
    Publication date: January 23, 2020
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
  • Publication number: 20190321414
    Abstract: Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 24, 2019
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Robert P. Lanza, Shi-Jiang Lu, Wei Wang
  • Patent number: 10426799
    Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.
    Type: Grant
    Filed: December 21, 2013
    Date of Patent: October 1, 2019
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
  • Publication number: 20190290701
    Abstract: Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.
    Type: Application
    Filed: February 25, 2019
    Publication date: September 26, 2019
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Robert P. Lanza, Shi-Jiang Lu, Wei Wang
  • Publication number: 20190282622
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 19, 2019
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Irina V. Klimanskaya, Robert P. Lanza
  • Publication number: 20190175656
    Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.
    Type: Application
    Filed: September 7, 2018
    Publication date: June 13, 2019
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Erin Anne Kimbrel, Robert P. Lanza, Jianlin Chu, Nicholas Arthur Kouris
  • Patent number: 10307444
    Abstract: Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 4, 2019
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Robert P. Lanza, Shi-Jiang Lu, Wei Wang
  • Publication number: 20190060370
    Abstract: Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.
    Type: Application
    Filed: July 2, 2018
    Publication date: February 28, 2019
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Robert P. Lanza, Shi-Jiang Lu, Wei Wang